Tegafur,Gimeracil and Oteracil Potassium

Generic Name: Tegafur,Gimeracil and Oteracil Potassium

Brand Names: -

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Indication: 用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of S-1 in Combination With Radiotherapy in Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: S-1
Radiation: Radiation therapy

First Posted Date: 2013-04-15

Last Posted Date: 2019-02-15

Lead Sponsor: Fudan University

Target Recruit Count: 105

Registration Number: NCT01831531

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1
Drug: Oxaliplatin
Drug: Cisplatin

First Posted Date: 2013-04-04

Last Posted Date: 2019-01-23

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 576

Registration Number: NCT01824459

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Postoperative Chemoradiotherapy With S-1 in Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1

First Posted Date: 2013-04-04

Last Posted Date: 2013-04-04

Lead Sponsor: Chonnam National University Hospital

Target Recruit Count: 46

Registration Number: NCT01824004

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun-Eup, Jeollanam-do, Korea, Republic of

Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: Gemcitabine
Drug: S-1

First Posted Date: 2013-03-21

Last Posted Date: 2018-05-16

Lead Sponsor: Kansai Hepatobiliary Oncology Group

Target Recruit Count: 70

Registration Number: NCT01815307

Locations: 🇯🇵
Osaka University, Graduate School of Medicine, Osaka, Japan

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Gastric Cancer

Interventions: Biological: DC-CIK
Drug: S-1
Drug: Cisplatin

First Posted Date: 2013-02-05

Last Posted Date: 2018-07-19

Lead Sponsor: Capital Medical University

Target Recruit Count: 63

Registration Number: NCT01783951

Locations: 🇨🇳
Capital Medical University Cancer Center, Beijing, Beijing, China

Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer

Phase 2

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: S-1

First Posted Date: 2012-12-12

Last Posted Date: 2012-12-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT01747707

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: S-1
Drug: cisplatin
Drug: oxaliplatin

First Posted Date: 2012-09-06

Last Posted Date: 2015-05-19

Lead Sponsor: Peking University

Target Recruit Count: 160

Registration Number: NCT01679340

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1
Drug: Cisplatin
Drug: Oxaliplatin

First Posted Date: 2012-08-23

Last Posted Date: 2015-11-30

Lead Sponsor: Min-Hee Ryu

Target Recruit Count: 338

Registration Number: NCT01671449

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun-eup, Hwasun-gun, Jeollanam-do, Korea, Republic of
🇰🇷
Dongnam Institute of Radiological and Medical Sciences, Busan, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of

and more 6 locations

Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: S-1

First Posted Date: 2012-07-20

Last Posted Date: 2012-07-20

Lead Sponsor: Chonnam National University Hospital

Target Recruit Count: 35

Registration Number: NCT01645748

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Gwangju, Jeollanamdo, Korea, Republic of

S-1-induced Lacrimal Drainage Obstruction

Conditions: Gastric Cancer

Interventions: Drug: S-1

First Posted Date: 2011-12-06

Last Posted Date: 2011-12-07

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 200

Registration Number: NCT01486472

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy